Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.
Simona OnaliMaria KalafateliAvik MajumdarRachel WestbrookJames O'BeirneGioacchino LeandroDavid PatchEmmanuel A TsochatzisPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
Patients with ascites on NSBBs did not have impaired survival compared to those not receiving NSSBs and interestingly this observation was also confirmed in the subgroup with refractory ascites. Our results suggest that NSBBs are not detrimental, but instead seem safe even in more advanced stages of cirrhosis in patients on a transplant waiting list.